Knight Therapeutics (TSX:GUD) 5-Year EBITDA Growth Rate : 12.90% (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics 5-Year EBITDA Growth Rate?

Knight Therapeutics's EBITDA per Share for the three months ended in Dec. 2024 was C$0.24.

During the past 12 months, Knight Therapeutics's average EBITDA Per Share Growth Rate was 66.70% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 10.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 12.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Knight Therapeutics was 28.80% per year. The lowest was -9.40% per year. And the median was 7.30% per year.

Competitive Comparison of Knight Therapeutics's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Knight Therapeutics's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's 5-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

Knight Therapeutics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Knight Therapeutics (TSX:GUD) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Knight Therapeutics 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Knight Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

KHTRF:USA 04K:Germany

Address

3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8

Website

https://www.gud-knight.com

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region.

Executives

Sime Armoyan	10% Security Holder
Samira Sakhia	Director, Senior Officer
Amal Khouri	Senior Officer
Jonathan Ross Goodman	Director, Director or Senior Officer of 10% Security Holder
Robert Nathaniel Lande	Director
Janice Jean Murray	Director
Nicolas Sujoy	Director
Long Zone Holdings Inc.	10% Security Holder
Arvind Utchanah	Senior Officer
Michael Joseph Tremblay	Director
James Gale	Director
Michael Dehn	Director, Senior Officer
Andrew Moor	Senior Officer
Patrick Mcclymont	Senior Officer
Kevin Drew Nabholz	Director

Knight Therapeutics Headlines

No Headlines